Catheter Precision, Inc. engages in the design, manufacture and sale of medical devices and technologies for cardiac electrophysiology. It offers the Amigo Remote Catheter System for accurate positioning, manipulation, and stable control of catheters for use by electrophysiologists in the diagnosis and treatment of abnormal heart rhythms. The company was founded by David Jenkins in September 2002 and is headquartered in Fort Mill, SC.
相关临床试验
2
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
2
100.0%
暂无批准数据
- Catheter Precision presented new clinical data for both VIVO and LockeT systems at the 47th Annual Heart Rhythm Society meeting, with over 10,000 professionals in attendance. - A novel study demonstrated VIVO's feasibility in using intracardiac electrodes rather than surface ECG to accurately identify ventricular tachycardia, potentially providing safer VT diagnosis. - New peer-reviewed publications validated both products, with LockeT showing high procedural success in 139 patients and VIVO accurately predicting arrhythmogenic substrate in 31 patients. - The research represents significant advancement in electrophysiology procedures, with VIVO improving workflow efficiency and LockeT demonstrating effective venous closure strategy.
- Catheter Precision has agreed to sell its atherectomy catheter technologies, including FDA approvals and patents, to a strategic acquirer for $15,000 upfront cash plus equity and royalty arrangements. - The divestiture aims to enhance capital efficiency and sharpen focus on the company's high-growth electrophysiology platform for treating cardiac arrhythmias. - The transaction includes a 5% equity stake in the acquiring company and a ten-year royalty agreement with rates ranging from 1.5% to 3% based on quarterly net sales performance. - Catheter Precision shares declined 5.05% following the announcement, with the stock trading 75.82% below its value from 12 months ago.
- Catheter Precision secured its first purchase order for LockeT at Mater Private Hospital in Dublin, Ireland's largest electrophysiology center performing over 1,000 EP procedures annually. - The suture retention device demonstrated rapid adoption with 52 staff members trained in just two days, highlighting its intuitive design and operational efficiency. - This expansion marks Ireland as the eighth European country to adopt LockeT since receiving CE Mark approval, strengthening the company's global electrophysiology market position.
- Catheter Precision has enrolled the first three patients in the LockeT Compare Study, a single-center physician-initiated trial evaluating up to 100 patients. - The study compares the safety profile of LockeT suture retention device against internal closure devices for managing groin complications after cardiac catheter procedures. - Previous clinical data demonstrates that LockeT is safe, effective, and reduces procedural costs while maintaining current hospital workflows. - The company believes the external device mechanism may reduce thrombotic episodes compared to internal closure devices, potentially improving patient safety outcomes.
• Catheter Precision completed acquisition of Cardionomic's heart failure assets through its 82% owned subsidiary, expanding into acute decompensated heart failure treatment. • The acquired CPNS System uses electrical stimulation via pulmonary artery catheter to target autonomic cardiac nerves, addressing over 1 million annual U.S. hospitalizations for ADHF. • Initial pilot studies showed positive results for the neuromodulation therapy, though the company acknowledges significant development challenges and regulatory hurdles ahead. • The acquisition represents a strategic expansion beyond Catheter Precision's core cardiac electrophysiology focus into the broader heart failure treatment market.
